I. Length of Authorization

Coverage will be provided for four months and may be renewed.

II. Dosing Limits

a. Max Units (per dose and over time)
   - Acute radiation exposure
     - 12 billable units weekly for 2 doses
   - All other indications:
     - 12 billable units per 14 days for all other indications

III. Initial Approval Criteria

Fulphila may be considered medically necessary if one of the below conditions are met AND use is consistent with the medical necessity criteria that follow:

- The patient is contraindicated or has failed treatment with Neulasta AND Udenyca††; OR
- The patient is continuing previously established therapy with Fulphila for their current chemotherapy regimen; AND
- A member does not have access to, or benefits for, home health services; OR
- A member is expected to receive G-CSF for 5 consecutive days or more; OR
- Fulphila is used in combination with one of the following chemotherapy regimens*:
  - Bladder Cancer:
- Dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin)
  - Breast Cancer:
    - Dose dense AC followed by T (doxorubicin, cyclophosphamide, paclitaxel)
  - Non-Hodgkin's Lymphoma:
    - Dose dense CHOP-14 (cyclophosphamide, doxorubicin, vincristine, prednisone)

*Pegylated filgrastim is the only G-CSF product used in the published clinical trials for these regimens. The requesting provider should provide journal citations supporting this request for regimens other than those listed.*

**Coverage for Fulphila™ (pegfilgrastim-jmdb) is provided in the following conditions:**

**Prophylactic use in patients with non-myeloid malignancy†**
- Patient is undergoing myelosuppressive chemotherapy with an expected incidence of febrile neutropenia of 20% or greater §; **OR**
- Patient is undergoing myelosuppressive chemotherapy with an expected incidence of febrile neutropenia of 10% or greater § and one or more of the following co-morbidities:
  - Elderly patients (age 65 or older)
  - History of recurrent febrile neutropenia from chemotherapy
  - Extensive prior exposure to chemotherapy
  - Previous exposure of pelvis, or other areas of large amounts of bone marrow, to radiation
  - Pre-existing neutropenia (ANC ≤ 1000/mm3) or bone marrow involvement with tumor
  - Patient has a condition that can potentially increase the risk of serious infection (i.e. HIV/AIDS)
  - Infection/open wounds
  - Recent surgery
  - Poor performance status
  - Poor renal function (creatinine clearance <50)
  - Liver dysfunction (elevated bilirubin >2.0)
  - Chronic immunosuppression in the post-transplant setting including organ transplant

**Patient who experienced a neutropenic complication from a prior cycle of the same chemotherapy ‡**

**Patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome) ‡**

†FDA-labeled indication, ‡ Compendia recommended indication
†† Medicare members are not subject to this step therapy

§ expected incidence of febrile neutropenia percentages for myelosuppressive chemotherapy regimens can be found in the NCCN Myeloid Growth Factors Clinical Practice Guideline at NCCN.org

IV. Renewal Criteria

Same as initial prior authorization policy criteria

V. Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute radiation exposure</td>
<td>6 mg subcutaneously weekly for 2 doses (Use weight based dosing below for pediatrics weight &lt; 45 kg)</td>
</tr>
<tr>
<td>All other indications</td>
<td>&lt; 10 kg = 0.1 mg/kg 10-20 kg = 1.5 mg 21-30 kg = 2.5 mg 31-44 kg = 4 mg 45 kg and up = 6 mg</td>
</tr>
<tr>
<td></td>
<td>Dosed no more frequently than every 14 days</td>
</tr>
</tbody>
</table>

*Do not administer within 14 days before and 24 hours after administration of cytotoxic chemotherapy

Revision History

12/18/2018 Added Step therapy to use Neulasta AND Udenyca prior to initiating Fulphila therapy.

Applicable Procedure Codes

Q5108 Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg

Applicable NDCs

67457-0833-06 Fulphila 6 mg prefilled syringe

Applicable Diagnosis Codes

D70.1 Agranulocytosis secondary to cancer chemotherapy
D70.9 Neutropenia, unspecified
T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs initial encounter
T45.1X5D Adverse effect of antineoplastic and immunosuppressive drugs subsequent encounter
T45.1X5S Adverse effect of antineoplastic and immunosuppressive drugs sequela
Z41.8 Encounter for other procedures for purposes other than remedying health state
Z48.290 Encounter for aftercare following bone marrow transplant
Z51.11 Encounter for antineoplastic chemotherapy
Z51.12 Encounter for antineoplastic immunotherapy
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z51.89</td>
<td>Encounter for other specified aftercare</td>
</tr>
<tr>
<td>Z52.001</td>
<td>Unspecified donor, stem cells</td>
</tr>
<tr>
<td>Z52.011</td>
<td>Autologous donor, stem cells</td>
</tr>
<tr>
<td>ZZ52.091</td>
<td>Other blood donor, stem cells</td>
</tr>
<tr>
<td>Z94.81</td>
<td>Bone marrow transplant status</td>
</tr>
<tr>
<td>Z94.84</td>
<td>Stem cells transplant status</td>
</tr>
</tbody>
</table>

References